Organon & Co Stock - Long-term strategy in women’s health and biosimilars
20.06.2026 - 16:59:29 | ad-hoc-news.de
Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 16:57 CET. Details in the imprint.
Organon & Co (US68622V1061) is a New Jersey based pharmaceuticals group focused on women’s health, established brands and biosimilars after its 2021 spin-off from Merck & Co. With no major fresh headlines today, the spotlight is on its long-term business model and strategic positioning.
All news and key data on Organon & Co stock
Track recent filings, press releases and price data on Organon & Co to see how its women’s health and biosimilars focus translates into the stock’s long-term profile.
How Organon describes its business
Organon positions itself as a global healthcare company built around three pillars: women’s health, established brands and biosimilars, according to its own corporate profile and latest Form 10-K filing with the SEC. SEC filings overview
Women’s health includes contraceptives, fertility treatments and other therapies tailored to female patients, while established brands are legacy medicines primarily in cardiovascular, respiratory, dermatology and pain. Biosimilars are developed with partners to target high-cost biologics.
Long-term strategy and focus areas
The company’s long-term strategy emphasizes growth in under-served women’s health indications, geographic expansion of its established brands portfolio and ramp-up of biosimilar launches in oncology and immunology. Management highlights opportunities in emerging markets and policy-driven access programs. Company overview
Organon also targets margin support through disciplined cost control, optimized manufacturing and focused R&D rather than broad, high-risk discovery. Capital allocation priorities center on debt reduction following the spin-off, a modest dividend and selective business development.
What the company sells
Organon generates revenue mainly from contraceptives such as Nexplanon/Implanon NXT, a long-acting reversible contraceptive implant, along with established medicines like asthma drug Singulair and fertility products including Follistim. In biosimilars, it co-commercializes products such as Renflexis, a biosimilar to Remicade.
Where the stock trades today
Organon & Co shares (US68622V1061) most recently closed on the New York Stock Exchange at $13.44 on 06/18/2026, 15:59 Eastern Time, giving the company a market capitalization of roughly $3.53 billion based on data from MarketBeat. MarketBeat quote and profile
Key facts on Organon & Co stock
- Company: Organon & Co.
- ISIN: US68622V1061
- WKN: A3CTDH
- Ticker: OGN
- Venue: NYSE
- Price (as of 06/18/2026, 15:59 ET): 13.44 USD
- Market cap: 3.53 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: not a member of the S&P 500 or Dow; trades on the NYSE as a standalone mid-cap
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
